Sichuan Huiyu Pharmaceutical Shareholder Wang Xiaopeng Plans to Reduce Holdings of No More Than 12.708 Million Shares, Accounting for 3% of Total Share Capital

Log in to Sina Finance App and search for [Disclosure of Information] to see more evaluation levels.

On March 17, Sichuan Huiyu Pharmaceutical Co., Ltd. (hereinafter referred to as “Huiyu Pharmaceutical”) announced a shareholder share reduction plan. Shareholder Wang Xiaopeng plans to reduce no more than 12.708 million shares, accounting for 3% of the company’s total share capital, through centralized bidding and block trades within the next three months due to personal funding needs.

Basic Information on Shareholders and Reduction Subjects

The announcement shows that as of the disclosure date, Wang Xiaopeng holds 16.698125 million Huiyu Pharmaceutical shares, accounting for 3.942% of the total share capital. These shares were acquired before the company’s initial public offering and have been unlocked for trading since October 26, 2022. Wang Xiaopeng is not a controlling shareholder, actual controller, or a person acting in concert of the company, nor does he hold more than 5% of the shares directly, nor is he a director, supervisor, or senior management of the company. He is a shareholder with less than 5% and has no persons acting in concert.

Details of the Reduction Plan

The main contents of Wang Xiaopeng’s reduction plan are as follows:

The announcement states that if the company distributes dividends, issues shares, capital reserve increases, or rights issues during the reduction period, the number of shares to be reduced will be adjusted accordingly.

Historical Reduction Review

According to the announcement, Wang Xiaopeng has previously reduced shares in the past 12 months. From October 24, 2025, to January 21, 2026, he reduced 339,432 shares, accounting for 0.08% of the company’s total share capital, at prices ranging from 20.37 yuan/share to 21.08 yuan/share. The pre-disclosure date for this reduction plan was September 25, 2025.

Commitments and Risk Tips Related to the Reduction Plan

Wang Xiaopeng previously made commitments to reduce shares, including complying with relevant laws, regulations, and stock exchange rules, and reducing shares through legal means such as centralized bidding and block trades after the lock-up period expires. The company will announce the reduction three trading days in advance and strictly fulfill information disclosure obligations. The current reduction plan is consistent with these previous commitments.

The announcement indicates that there are risks of uncertainty in the implementation of this reduction plan. Wang Xiaopeng will decide whether and how to implement it based on market conditions, the company’s stock price, and other factors. The timing, price, and amount of reduction are uncertain. This reduction will not lead to a change in the company’s control. Huiyu Pharmaceutical states that shareholders will strictly comply with the Securities Law, the STAR Market Listing Rules, and other laws and regulations, fulfill commitments, and disclose information in a timely manner.

The board of directors of Sichuan Huiyu Pharmaceutical issued this announcement on March 17, 2026.

Disclaimer: The market carries risks; investment should be cautious. This article is automatically published by an AI model based on third-party databases and does not represent Sina Finance’s views. All information in this article is for reference only and does not constitute personal investment advice. Please refer to the actual announcement for any discrepancies. If you have questions, contact biz@staff.sina.com.cn.

Click to view the original announcement>>

Massive information, precise interpretation, all on Sina Finance App.

Editor: Xiao Lang Kuai Bao